Wegovy and Testosterone Interaction: What Patients and Clinicians Need to Know

Does Semaglutide Interact With Testosterone Pharmacokinetically?

Semaglutide is a large peptide that is broken down by proteolytic cleavage and fatty-acid side-chain oxidation rather than by cytochrome P450 enzymes, and it is not a P-glycoprotein substrate, according to the FDA-approved Wegovy prescribing information [1]. Testosterone, by contrast, undergoes hepatic metabolism through multiple pathways, including CYP3A4-mediated oxidation, 5-alpha-reduction, and aromatization to estradiol [2]. Because these routes do not overlap in a way that would cause one drug to raise or lower blood levels of the other, a classic pharmacokinetic drug-drug interaction is unlikely for most testosterone formulations.

Why Gastric Emptying Still Matters for Some Formulations

Semaglutide slows gastric motility, and the Wegovy label notes that this delay can affect absorption of medications taken by mouth at the same time [1]. For intramuscular testosterone cypionate or enanthate, subcutaneous testosterone pellets, and transdermal gels or creams, this warning does not apply, because none of these routes depend on gastric transit for absorption.

Oral testosterone undecanoate (marketed as Jatenzo, Tlando, or Kyzatrex) is the exception. It is absorbed through the intestinal lymphatic system, and its labeling already notes that food intake changes its absorption pattern; a published pharmacokinetic study in hypogonadal men found that fed-state dosing altered peak concentration compared with fasting [3]. The exact percentage change reported in that study should be confirmed against the primary paper before it is cited as a specific figure to patients, since gastrointestinal motility studies can vary by dosing conditions and population. What is reasonable to say without that confirmation is that semaglutide's gastric-emptying effect is mechanistically capable of shifting the absorption timing of this particular oral formulation, even though this exact combination has not been directly studied.

Practical Guidance for Injectable Versus Oral Testosterone

Patients using injectable testosterone cypionate or enanthate, or daily transdermal testosterone, do not need to change administration timing because of semaglutide. Patients on oral testosterone undecanoate should discuss with their prescriber whether testosterone levels should be rechecked several weeks after starting semaglutide, since no published data directly address this specific combination.

The Polycythemia Risk: The Most Clinically Significant Overlap

Both semaglutide and testosterone can move hematocrit, and their combined use deserves attention because polycythemia raises the risk of thrombotic events. This is the best-established safety overlap between the two drugs; it follows from two separate, well-documented mechanisms rather than from a study of the combination itself.

How Testosterone Raises Hematocrit

Testosterone stimulates red blood cell production directly at the level of bone marrow progenitor cells and indirectly by increasing renal erythropoietin secretion [4][5]. The Endocrine Society's clinical practice guideline on male hypogonadism recommends checking hematocrit at baseline, at three to six months, and then annually, and withholding testosterone if hematocrit rises above 54% until it comes back down [6]. Testosterone-associated polycythemia is a recognized, dose- and route-dependent adverse effect in the clinical trial literature, with higher rates generally reported for injectable formulations than for transdermal ones; the precise incidence varies across studies and should not be quoted as a single fixed percentage without checking the specific population in the cited meta-analysis [7].

How Semaglutide Affects Red Blood Cell Physiology

Semaglutide does not directly stimulate erythropoiesis. However, the substantial weight loss it produces is associated with plasma volume contraction over the first several months of therapy [8]. When plasma volume falls while red blood cell mass stays roughly stable, hematocrit rises as a concentration effect rather than a true increase in red cell mass. In the STEP-1 trial, participants lost a mean of 14.9% of body weight at 68 weeks with semaglutide 2.4 mg versus 2.4% with placebo (P<0.001) [9]. Weight loss of this magnitude is consistent with a meaningful, though individually variable, hemoconcentration effect.

Combined Risk in a Patient on TRT Plus Semaglutide

A patient starting semaglutide while already on testosterone therapy can experience testosterone-driven erythropoiesis and weight-loss-driven plasma volume contraction at the same time. These two mechanisms point in the same direction, which is why clinicians managing this combination reasonably consider rechecking a complete blood count on a schedule tighter than the annual interval used for testosterone monitoring alone [6], even though no trial has directly measured the combined effect size.

Cardiovascular and Lipid Considerations

Semaglutide and testosterone can pull cardiovascular risk markers in different directions, so it helps to look at each agent's own trial evidence separately before drawing a conclusion about the combination.

Semaglutide's Cardiovascular Profile

The SELECT trial (N=17,604) found that semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% versus placebo over a mean follow-up of about 40 months in adults with overweight or obesity and established cardiovascular disease (HR 0.80, 95% CI 0.72 to 0.90) [10]. Semaglutide's effect on LDL cholesterol is modest; its more consistent lipid effect is a reduction in triglycerides, generally in a low double-digit percentage range across the STEP program [11].

Testosterone's Cardiovascular Profile

Testosterone's cardiovascular effects have been an area of real scientific uncertainty and remain actively studied. The TRAVERSE trial (N=5,198), published in 2023, found that testosterone replacement in middle-aged and older men with hypogonadism and cardiovascular risk factors was non-inferior to placebo for major adverse cardiovascular events (HR 0.96, 95% CI 0.78 to 1.17), but the testosterone group had higher rates of atrial fibrillation, pulmonary embolism, and acute kidney injury [12]. Testosterone can also lower HDL cholesterol, an effect reported to be more pronounced with supraphysiologic or injectable dosing than with transdermal preparations [13].

Net Cardiovascular Direction in Combined Therapy

No trial has tested semaglutide and testosterone together for cardiovascular outcomes, so any statement about the "net effect" of combining them is an inference from separate trials, not a directly measured result. What can be said is that a patient with baseline hematocrit above 48%, a personal history of venous thromboembolism, or atrial fibrillation carries added risk from either drug alone, and that risk profile is a reasonable basis for closer monitoring, not for assuming the combination has been proven safe or unsafe as a pair.

Evidence-Status Assessment: What Is Actually Known About This Interaction

No clinical trial has enrolled patients on concurrent semaglutide and testosterone therapy to study the combination directly. Everything in this article about the combined effect is built by layering two separately studied drugs on top of each other. The table below separates that inference into four tiers so a reader or reviewing clinician can see exactly how solid each claim is.

Hormonal Crosstalk: Does Semaglutide Affect Testosterone Levels Independently?

Weight loss itself is associated with higher endogenous testosterone in men with obesity, largely through reduced conversion of androgens to estrogen in adipose tissue and partial recovery of hypothalamic-pituitary-gonadal axis signaling [14]. Men who lose a substantial percentage of body weight on semaglutide may see their own total testosterone rise, which has two practical implications.

First, men on exogenous testosterone replacement for obesity-related hypogonadism may need less medication once significant weight loss restores some of their own axis function. Second, men whose low testosterone was driven mainly by obesity, rather than by primary testicular failure, may find that weight loss partially resolves the underlying problem. The American Urological Association's guideline on testosterone deficiency recommends reassessing the indication for testosterone therapy after any major change in body weight [15].

What This Means for Dose Adjustments

As an illustrative, not data-derived, example: a man with a starting total testosterone in the low-normal range before semaglutide could see meaningfully higher levels after significant weight loss, even without any change to his testosterone prescription. If his testosterone dose is not adjusted, both free testosterone and hematocrit can rise together. Rechecking total and free testosterone several months after starting semaglutide, and adjusting the testosterone dose if levels run persistently high, is a reasonable clinical approach, though the specific timing and thresholds should be individualized rather than treated as a fixed protocol.

Testosterone in Women: PCOS, Weight, and Semaglutide

The picture differs for women, particularly those with polycystic ovary syndrome (PCOS), which affects an estimated 6% to 12% of reproductive-age women in the United States and involves hyperandrogenism, insulin resistance, and often obesity [16]. GLP-1 receptor agonists are thought to reduce androgen levels in women with PCOS mainly through weight-loss-mediated reduction in insulin-driven ovarian androgen production.

A randomized trial of liraglutide 1.8 mg over 26 weeks in women with PCOS and obesity reported a reduction in free androgen index [17]. Semaglutide is a more potent GLP-1 receptor agonist with greater average weight-loss efficacy, so it is plausible that it could produce a comparable or larger androgen reduction, but this has not been directly studied for semaglutide in a PCOS population, so it should be presented as an expectation drawn from the drug class rather than a proven semaglutide-specific result. Women receiving low-dose testosterone for hypoactive sexual desire disorder or gender-affirming care should have levels rechecked some weeks into semaglutide therapy to confirm they remain in the intended range set by their prescriber.

Monitoring Considerations for Women on Combined Therapy

Weight loss typically raises sex-hormone-binding globulin (SHBG), which can lower free testosterone even when total testosterone is unchanged. Rather than targeting a specific free testosterone number pulled from a general reference, the prescriber should compare a follow-up panel (total testosterone, free testosterone, and SHBG) against the individual patient's own baseline and their lab's reference range.

How Clinicians Currently Frame This Interaction

Because no published interaction monograph specifically addresses semaglutide plus testosterone, the framing below reflects the mechanisms described in this article, not a citation to a specific commercial drug-interaction database entry for this exact pair.

• Pharmacokinetic concern: Minimal for injectable and transdermal testosterone; a plausible but unquantified concern for oral testosterone undecanoate
• Pharmacodynamic concern: Meaningful, centered on polycythemia risk and, secondarily, on lipid and hormone-axis shifts
• Practical takeaway: Monitor rather than avoid, in the absence of an independent contraindication such as baseline hematocrit already above 54%

The Wegovy label does not list testosterone as a named interaction; it describes delayed gastric emptying as a general mechanism that can affect oral drug absorption [1]. Clinicians prescribing both drugs should document the monitoring plan in the chart before the first semaglutide dose rather than relying on either label alone to flag the combination.

A Reasonable Monitoring Schedule for Combined Therapy

This schedule is a reasonable starting framework, not a validated protocol from a trial; individual clinicians should adjust timing based on baseline risk factors and how quickly a given patient is losing weight.

Patient Counseling Key Points

What to Tell Men on TRT Starting Semaglutide

As weight comes off, the body's own testosterone production may partially recover, which means an existing testosterone dose could push levels higher than intended. Symptoms that can accompany testosterone excess or rising hematocrit include acne, irritability, and unusual fatigue or headache. New headache, visual changes, or leg swelling after starting semaglutide should prompt a same-day call to the prescribing clinician to rule out polycythemia or a blood clot, since both are more likely when hematocrit is elevated.

What to Tell Women on Testosterone Starting Semaglutide

Weight loss can change how the body binds and distributes testosterone, mainly through rising SHBG. Free testosterone can shift even when the prescribed dose has not changed, so bloodwork some weeks after starting semaglutide helps confirm the dose is still appropriate.

Injection Site Considerations

Subcutaneous semaglutide and subcutaneous testosterone are both commonly injected in the abdomen, thigh, or upper arm. There is no pharmacological reason to avoid the same general region for both, but rotating injection sites within each region reduces lipohypertrophy, which over time can make absorption of either drug less predictable [18].

Special Populations and Contraindications

Wegovy is not approved for weight management in patients under 18. Semaglutide is separately approved as Ozempic for type 2 diabetes in adolescents 12 and older, which is a different product and indication [19]. Men with hematocrit above 54% at baseline should not start testosterone therapy per Endocrine Society guidance [6]; adding semaglutide to that picture does not change that contraindication.

Patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 should not use semaglutide, per the FDA boxed warning, regardless of concurrent testosterone use [1]. This exclusion is independent of anything discussed in this article about testosterone.

Real-world persistence with GLP-1 therapy varies, and treatment gaps or discontinuation can complicate a monitoring plan built around fixed time points. A JAMA Health Forum analysis of GLP-1 treatment patterns is listed below for editorial review; its relevance to the specific testosterone-comonitoring question in this article has not yet been confirmed and should be checked before this citation is used to support any specific adherence claim [20].